Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic

This article was originally published in The Gray Sheet

Executive Summary

Divestiture of non-occlusive arterial pump line to Baxter settles Federal Trade Commission antitrust charges in connection with the company's $106 mil. acquisition of Avecor on March 8, FTC announces March 10. Avecor's perfusion device, which is currently in the early stages of gaining market acceptance, offers consumers advantages over Medtronic's Bio-Pump, FTC notes
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT011505

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel